Enhancing SIV-specific immunity in vivo by PD-1 blockade

Area of Science:

• Immunology
• Virology
• Immunotherapy

Background:

• Chronic immunodeficiency virus infections cause impaired immune responses.
• Restoring virus-specific immunity is crucial for controlling disease progression.
• Programmed death 1 (PD-1) is a co-inhibitory receptor that can suppress immune function.

Purpose of the Study:

• To evaluate the safety and immune restoration potential of PD-1 blockade in chronic simian immunodeficiency virus (SIV) infection.
• To assess the impact of PD-1 blockade on cellular and humoral antiviral immunity.
• To determine if PD-1 blockade can reduce viral load and improve survival in SIV-infected macaques.

Main Methods:

• Administered an antibody targeting PD-1 to SIV-infected macaques.
• Monitored immune cell populations (CD8 T cells, B cells) and function.
• Measured SIV-specific antibody levels and plasma viral load.
• Assessed treatment efficacy in early and late chronic infection stages, and under lymphopenic conditions.

Main Results:

• PD-1 blockade was well-tolerated and led to rapid expansion of virus-specific CD8 T cells with enhanced function in blood and gut.
• Increased proliferation of memory B cells and elevated SIV envelope-specific antibodies were observed.
• Significant reductions in plasma viral load and prolonged survival of SIV-infected macaques were achieved.
• Efficacy was demonstrated in both early and late chronic infection phases, even with severe lymphopenia.

Conclusions:

• Blocking the PD-1 inhibitory pathway effectively enhances both cellular and humoral immune responses during pathogenic immunodeficiency virus infection.
• PD-1 blockade represents a promising therapeutic strategy for controlling simian and potentially human immunodeficiency virus infections.
• This approach offers a novel avenue for immune restoration in the context of chronic viral infections.